Bassaganya-Riera Josep's Form 4 filing
Landos Biopharma, Inc. (LABP) · filed Dec 15, 2021
- Accession no.
- 0001843575-21-000009
- Filed
- Dec 15, 2021
- Trade date
- Dec 13-15, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $644.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bassaganya-Riera JosepCIK 0001843575 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 13, 2021 | common stock | SSaleDisposed | −40,000 | $5.37 | −$214,800 | 5,231,354 | Indirect | |
| Dec 14, 2021 | common stock | SSaleDisposed | −42,000 | $5.10 | −$214,200 | 5,189,354 | Indirect | |
| Dec 15, 2021 | common stock | SSaleDisposed | −43,000 | $5.02 | −$215,860 | 5,146,354 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.